Biotechnology News and Research

RSS

Medidata Solutions introduces Grants Manager 3.0 to select correct procedure for budgeting in trial

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today introduced Medidata Grants Manager 3.0, the newest version of its trial budgeting application in use today by many of the innovative clinical research sponsors in the life sciences industry. Now offered as a web-based solution, Grants Manager 3.0 enables users to build clinical trial grant budgets and benchmark them against Medidata's unique PICAS database of negotiated trial costs without the need to install software.

14 Jun 2010

Vitrolife enters into two year collaboration agreement with University of Melbourne

Vitrolife has entered into a two year collaboration agreement with University of Melbourne regarding collaboration with the stem cells expertise of the development of clinical grade stem cell media.

14 Jun 2010

Discovery Labs secures new Committed Equity Financing Facility with Kingsbridge

Discovery Laboratories, Inc., announced today that it has secured a new Committed Equity Financing Facility (2010 CEFF) with Kingsbridge Capital Limited, a private investment group, in which Kingsbridge has committed to provide up to $35 million of capital over a three-year period through the purchase of up to approximately 31.6 million newly-issued shares of Discovery Labs' common stock.

14 Jun 2010

M&A issues in bio-pharma mega-mergers

The bio-pharma mega-mergers that grabbed headlines last year - Roche + Genentech, Pfizer + Wyeth, and Merck + Schering-Plough - are now in the critical post-integration period and the acquiring companies are finding out how well they planned and executed their integration plans.

14 Jun 2010

O2h signs agreement to provide Senexis with chemistry services to support patent filing

Executives from Senexis Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) under which O2h will provide Senexis with chemistry services to support a patent filing on a novel chemical series that have shown potential in pre-clinical models, as disease modifying treatments for Alzheimer's Disease.

14 Jun 2010

New bacterial strain could help in long-term cleanup of oil spills

Researchers have discovered a new strain of bacteria that can produce non-toxic, comparatively inexpensive "rhamnolipids," and effectively help degrade polycyclic aromatic hydrocarbons, or PAHs - environmental pollutants that are one of the most harmful aspects of oil spills.

14 Jun 2010

USPTO issues patent covering methods for enhancing RNA silencing activity of RNAi agents

Silence Therapeutics plc announces the issuance of United States patent 7,732,593, titled Methods and Compositions For Controlling Efficacy of RNA Silencing, by the United States Patent and Trademark Office. The issued patent, which is based on the seminal research of Phillip D. Zamore, Ph.D., Howard Hughes Medical Institute Investigator, the Gretchen Stone Cook Chair of Biomedical Sciences, and Professor of Biochemistry & Molecular Pharmacology at University of Massachusetts Medical School, generally claims methods of enhancing the RNA silencing activity of RNA interference (RNAi) agents through certain structural modifications.

14 Jun 2010

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

News on the progress of a new trial may give new hope to patients with HIV who are dependent on anti-HIV drugs. The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from Atlanta-based, GeoVax Inc, a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines.

14 Jun 2010

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Data presented at the 15th European Hematology Association (EHA) congress in Barcelona, highlights the impact of febrile neutropenia (FN) on chemotherapy delivery in non-Hodgkin lymphoma (NHL) patients. The IMPACT NHL study showed that unplanned hospitalisations, delays in chemotherapy and reductions of chemotherapy dose leading to suboptimal relative dose intensity (RDI) of chemotherapy were more frequent in patients who experienced FN than those who did not.

14 Jun 2010

Scientists manipulate simple bacteria into constructing internal compartments for biofuels, vaccines

Scientists at the University of Kent and University College Cork have manipulated simple bacteria into constructing internal compartments where biofuels and vaccines can be produced.

14 Jun 2010

PolyMedix awarded $150,000 grant to support development of antimicrobial sutures to reduce SSIs

A new discovery may help curb surgical site infections through the use of a novel antibiotic agent that can be incorporated into sutures. SSIs are the third most common hospital-acquired infection and may be associated with severe morbidity and mortality. Since more than 60% of SSIs occur in the area of the incision, the use of sutures coated with an antibacterial agent called PolyCides, created by Radnor, PA-based PolyMedix Inc., may reduce infection rates.

14 Jun 2010

Despite economic downturn, NJ biotechnology industry continues to grow

The number of biotechnology companies operating in New Jersey continues to increase significantly despite the downturn in the economy, ongoing difficulties in obtaining venture capital and other forms of funding and a contraction in the biotechnology and pharmaceutical industries at both the state and national levels, according to initial results from an industry survey released today by BioNJ, the trade association for the biotechnology industry in New Jersey.

14 Jun 2010

BIOTECanada congratulates CPHA on 100 years of leadership in public health

As a community partner of the Canadian Public Health Association, BIOTECanada, on behalf of Canada's biotechnology industry, congratulates the CPHA on 100 years of leadership in public health.

11 Jun 2010

ACT's hESC line MA135 approved for federal funding

Advanced Cell Technology, Inc. announced today that human embryonic stem cell line MA135 was unanimously approved for federal funding at the 100th Meeting of the Advisory Committee to the Director National Institutes of Health. In addition to MA135, seven additional stem cell lines derived at ACT are currently under review by the NIH.

11 Jun 2010

Sundise to implement Medidata Rave as its EDC and CDM solution

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Traditional Chinese Medicine company Sundise will implement Medidata Rave as its electronic data capture and clinical data management solution. Selected for its ability to offer a broad global reach with local in-country support, Medidata will work with Sundise to conduct its first U.S. trial for its TCM treatment for liver fibrosis and will play a key role in supporting the company's strategy to launch in the U.S.

11 Jun 2010

Takeda receives pricing approval for NESINA in Japan

Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited has received pricing approval for NESINA® (alogliptin) in Japan. NESINA, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April 16, 2010. Furiex collaborated with Takeda to develop this product.

11 Jun 2010

Patheon second-quarter total revenues increase 4.8% to $175.4 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the second quarter and six months ended April 30, 2010. Total revenues for the second quarter were $175.4 million or 4.8% higher than the same period last year.

11 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

Perceptive Informatics releases new web-based version of DataLabs Designer module

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today released a new web-based version of the DataLabs Designer™ module, which is part of Perceptive's DataLabs® Electronic Data Capture (EDC) solution. The web-based study design tool, which can be hosted by Perceptive, provides clinical study teams worldwide with online access to collaboratively design trials. This core capability assists in streamlining workflow and improving the efficiency of the study design process.

11 Jun 2010

New undergraduate major in health sector management and policy launched

The University of Miami School of Business Administration today announced that it will offer a new undergraduate major in health sector management and policy beginning in fall 2010. The major is designed to prepare students for business careers within the health care industry, as well as to pursue advanced degree programs in health administration, health economics, medical sociology and public health.

11 Jun 2010

Biotechnology News and Research

Medidata Solutions introduces Grants Manager 3.0 to select correct procedure for budgeting in trial

Vitrolife enters into two year collaboration agreement with University of Melbourne

Discovery Labs secures new Committed Equity Financing Facility with Kingsbridge

M&A issues in bio-pharma mega-mergers

O2h signs agreement to provide Senexis with chemistry services to support patent filing

New bacterial strain could help in long-term cleanup of oil spills

USPTO issues patent covering methods for enhancing RNA silencing activity of RNAi agents

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Scientists manipulate simple bacteria into constructing internal compartments for biofuels, vaccines

PolyMedix awarded $150,000 grant to support development of antimicrobial sutures to reduce SSIs

Despite economic downturn, NJ biotechnology industry continues to grow

BIOTECanada congratulates CPHA on 100 years of leadership in public health

ACT's hESC line MA135 approved for federal funding

Sundise to implement Medidata Rave as its EDC and CDM solution

Takeda receives pricing approval for NESINA in Japan

Patheon second-quarter total revenues increase 4.8% to $175.4 million

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Perceptive Informatics releases new web-based version of DataLabs Designer module

New undergraduate major in health sector management and policy launched

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News